Fibroepithelial polyp of urethra

Summary

Fibroepithelial polyp of urethra (MONDO:0006550) is a disease. A subtype of urethral disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fibroepithelial polyp of urethra
Mondo ID	MONDO:0006550
DOID	DOID:8108
NCIT	C6170
UMLS	C1336884
MedGen	234460
Anatomy (UBERON)	UBERON:0000057
Is cancer (heuristic)	no

Also known as: fibroepithelial polyp of the urethra · fibroepithelial polyp of urethra · urethra fibroepithelial polyp · urethra skin tag · urethral fibroepithelial polyp

Disease family

This is a subtype of urethral disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urethral disorder › fibroepithelial polyp of urethra

Related subtypes (9): prolapse of urethra, urethral obstruction, urethral intrinsic sphincter deficiency, urethral syndrome, urethral false passage, urethral calculus, urethral gland abscess, urethritis, urethra neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.